Page 2516 - Williams Hematology ( PDFDrive )

2487
2486 Index Index 2487

Receptor activator of NF-κB ligand indications, 2369 Regulatory T (T REG ) cells. See CD4+CD25+
(RANKL), 1077f, 1713, 1737, 1738f, massive, thrombocytopenia associated regulatory T (T REG ) cells
1739f with, 2014 Relapsed leukemia, 1401
Receptor down-modulation, 252–253 for myelodysplastic syndromes, 1357 Relative anemia, 506
Receptor of activated protein kinase C in newborns, 2371, 2372t Relative erythrocytosis, 872, 880
(RACK1), 487 in orthopedic patients, 2370 Remodelers (ATP-dependent chromatin
Receptor protein-tyrosine kinases (rPTKs), for paroxysmal nocturnal hemoglobinuria, remodeling complexes), 166–168,
230 579 166f
Receptor tyrosine kinases (RTKs), 249 patient blood management for avoidance Renal disease/dysfunction
Recessiveness, 147, 149 of, 2378 in acute hemolytic transfusion reaction,
Recombinant factor VIIa. See Factor VIIa in preterm infants, 2371, 2372t 2374
replacement red cell age and outcome of, 2376–2377 in acute myelogenous leukemia, 1381
Recombinant factor VIII. See Factor VIII for sickle cell disease, 776, 2371–2372 in AL amyloidosis, 1775, 1775t,
replacement in solid-organ transplant patient, 2374 1776–1777, 1781
Recombinant human erythropoietin. See for thrombocytopenia, 1541 in antiphospholipid syndrome, 2241
Erythropoiesis-stimulating agents Red marrow, 28 chronic, anemia of. See Anemia of chronic
(ESAs) Red pulp, spleen, 89f, 90, 90f kidney disease
Recombinant tissue plasminogen activator. Red thrombi, 2292 in disseminated intravascular coagulation,
See Alteplase; Reteplase; Reduced-intensity conditioning, for 2204, 2205t
Tenecteplase hematopoietic cell transplantation, dose modification in patients with, 316t
Recombination signal sequences (RSS), 1164 360–361, 367 in essential monoclonal gammopathy,
Recommended daily allowances (RDAs) Red urine, history of, 5 1723–1724
cobalamin, 589 Reed-Sternberg cells folate excretion and, 588
folate, 584 antigen receptor rearrangements, 1606 in hemolytic uremic syndrome,
iron, 618t genetic alterations and signaling pathways, 2258–2259
Rectal bleeding, 1987 1606 in myeloma, 1744–1745
Recurrence risk, 148, 150 histopathology, 1599f, 1605f polycythemia and, 878–879, 881
Recurring abnormality, 175t in Hodgkin lymphoma, 1599, 1599f, primary lymphoma, 1582
Red cell antigens, in newborns, 104 1605–1607, 1605f in sickle cell disease, 770
Red cell aplasia. See Pure red cell aplasia microenvironment, 1607 in thrombotic thrombocytopenic purpura,
Red cell clearance, splenic, 90–91 origin, 1606–1607 2254
Red cell count, 13–14 reprogramming, 1606 in Waldenström macroglobulinemia,
Red cell distribution width (RDW), 14 Reference ranges, 18–19, 18t, 19f 1791
Red cell enzyme disorders. See Erythrocyte Refractory anemia Renal transplantation
enzyme disorders with excess blasts (RAEB). See Oligoblastic for atypical hemolytic uremic syndrome,
Red cell exchange myelogenous leukemia (refractory 2261
adverse effects, 433 anemia with excess blasts) erythrocytosis following
indications for, 428t, 429t, 432 history, 1342 clinical features, 881
principles, 431 paroxysmal nocturnal hemoglobinuria epidemiology, 873
for protozoan disease, 432 and, 575t, 578 etiology and pathogenesis, 878–879
for sickle cell disease, 431–432 with ring sideroblasts (RARS), 178, 1343, therapy, 884
Red cell flicker, 469 1343t, 1349 hematopoietic cell transplantation for
Red cells. See Erythrocytes with ring sideroblasts with thrombocytosis tolerance of, 373–374
Red cell transfusion (RARS-T), 178, 1343, 1343t, 1349, Rendu-Osler-Weber disease. See Hereditary
ABO incompatibility and, 2330 1352 hemorrhagic telangiectasia (HHT)
adverse effects. See Iron overload; Refractory cytopenia Renin-angiotensin system (RAS), 487
Transfusion reactions of childhood, 178 Reperfusion therapy, 2295
for anemia of chronic renal disease, 554 with multilineage dysplasia, 1343, 1343t Replicative senescence, 132
for anemia of inflammation, 554, 554t paroxysmal nocturnal hemoglobinuria R-EPOCH regimen
for aplastic anemia, 522 and, 575t, 578 for Burkitt lymphoma, 1675t, 1676
for autoimmune hemolytic anemia, 837 with unilineage dysplasia, 178, 1343, 1343t for diffuse large B-cell lymphoma, 1629t,
for β-thalassemia, 751, 2372 Refractory leukemia, 1401 1630
in cardiovascular patients, 2369–2370 Refractory megaloblastic anemia, 608 for HIV-associated lymphoma, 1245, 1247
in children, 2371 Regadenoson, for sickle cell disease, 777t for lymphomatoid granulomatosis, 1635
in critically ill patients, 2369–2370, 2370t Regenerative medicine. See Multipotential for primary mediastinal large B-cell
for Diamond-Blackfan anemia, 540 cell therapy lymphoma, 1635

Kaushansky_index_p2393-2506.indd 2487 9/21/15 3:22 PM